Post-Infectious Autoimmune Encephalopathy.

What is post-infectious autoimmune encephalopathy?

Post-infectious autoimmune encephalopathy is a clinical framework for selected patients whose neurologic or neuropsychiatric symptoms follow an infectious trigger and where immune dysregulation or neuroinflammation is suspected. Patients can be adults or children. The term is descriptive rather than a single defined disease — the underlying biology varies, and evaluation is individualized.

Cautious language matters here. Not every post-viral symptom is autoimmune, and not every patient who feels unwell after an infection has an immune-mediated process driving their symptoms. The goal of evaluation is to identify which patients have findings that warrant an immune-focused approach — and which do not.

The COVID connection

Long COVID can include neurological symptoms such as difficulty thinking and concentrating, sleep problems, dizziness, depression and anxiety, headache, and post-exertional symptoms. The CDC and major academic centers recognize this constellation as common, varied, and incompletely understood. Only a subset of patients with persistent post-COVID symptoms warrants a dedicated immune or neuroimmune evaluation. The decision to pursue that evaluation is based on the symptom pattern, prior workup, and clinical context — not on a single test result.

What does it look like?

Reported features include:

• Brain fog — difficulty thinking clearly or holding focus
• Memory impairment, particularly short-term memory
• Attention and processing-speed problems
• Fluctuating cognition — better and worse days
• Mood or behavioral change after infection
• Fatigue that is accompanied by neurologic symptoms
• Dysautonomia-type symptoms: postural lightheadedness, palpitations, temperature dysregulation
• Sleep disruption
• In some patients, neuropsychiatric deterioration that emerged weeks to months after the index illness

How Dr. McNeil approaches evaluation

Evaluation is individualized but typically includes:

• A careful infection timeline, including the index illness and any subsequent infections
• Review of records from primary care, neurology, infectious disease, and other specialists
• Immune testing where appropriate — immunoglobulins, lymphocyte subsets, and other workup
• Inflammatory markers where they help
• Anti-neuronal antibody testing when clinically indicated, recognizing that a normal panel does not exclude an immune process
• Post-viral immune phenotyping when appropriate
• Coordination with neurology, infectious disease, primary care, and other treating specialists

Treatment approach

Treatment depends on what the evaluation finds. Possible approaches in selected patients include:

• Treatment of an ongoing infection if one is identified
• Symptom-directed care — sleep, autonomic, cognitive, and mood support, often through the appropriate specialists
• Anti-inflammatory or immunomodulatory therapy in selected cases when clinical criteria are met
• Continued physical and cognitive rehabilitation through the appropriate teams

IVIG, rituximab, and other immunotherapies are not standard for Long COVID and are not appropriate for every patient. They are considered only in selected patients when objective findings support an immune-mediated process and when other reasonable explanations have been considered.

Insurance and prior authorization

Dr. McNeil does not accept blanket insurance denials when the medical record supports treatment. For qualified patients, the team pursues the available authorization pathways — including written appeals, peer-to-peer discussions with insurance medical directors, and formal prior authorization review. Payers in this space often require strong documentation, objective findings, and clear medical necessity. Some carriers make this process harder than others. The practice continues to advocate for medically appropriate treatment regardless of insurance type.

To be clear: evaluation does not guarantee a diagnosis, and a diagnosis does not guarantee insurance approval for any specific therapy. Treatment decisions are individualized based on clinical findings and supported by objective documentation. Where treatment is appropriate, the team works hard on the patient's behalf.

Treatment pathway at Optimed Immunology

Every patient’s situation is different, but the decision logic for post-infectious autoimmune encephalopathy generally follows these steps. This is not a script — it is a structure that gets adapted to each patient’s history, findings, and goals.